openPR Logo
Press release

Hepatitis C Diagnosis & Treatment Market : Global Key Players - F. Hoffmann-La Roche Ltd, BMS, Merck & Co., Inc, Vertex Pharmaceuticals Incorporated

01-16-2018 05:07 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Hepatitis C Diagnosis & Treatment Market : Global Key Players - F.

Market Research Future published a Half-Cooked Research Report on “Global Hepatitis C Diagnosis and Treatment Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.

Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer.

According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer.

According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1569 .

The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc.

Global Hepatitis C Diagnosis and Treatment Market-Competitive Analysis

Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.
October, 2013 - Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline. According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.

October, 2013 - Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD). According to company reports, Bristol-Myers Squibb’s hepatitis C includes compounds with different mechanisms of action, biologics as well as small molecule direct-acting antivirals. These compounds were being studied as part of multiple treatment regimens with the goal of increasing SVR rates across different patient types. Moreover, company stated NS5A replication complex inhibitor daclatasvir (DCV) had been extensively studied in thousands of patients to date as a foundational agent for multiple DAA-based combination therapies and is currently in Phase III development. DCV has shown antiviral potency and pan-genotypic activity across HCV genotypes in vitro. DCV has a drug-drug interaction profile that supports its continued study in a variety of HCV combination regimens. However, Asunaprevir (ASV) is an NS3 protease inhibitor in Phase III development for hepatitis C as a component of DCV-based treatment regimens. BMS-791325 is a non-nucleoside inhibitor of the NS5B polymerase, currently in Phase II development for hepatitis C as a component of DCV-based treatment regimens. Lambda is an investigational type III interferon that has the potential to offer an alternative to alfa-interferon in patients for whom an interferon-based regimen is required or preferred.

Browse Complete Report at https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569 .

Depending on geographic region, Hepatitis C diagnosis & treatment market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally, Americas is the largest market for global Hepatitis C diagnosis and treatment with Europe in the second position. However, the developed regions market is stagnant and will continue to do so with Asia Pacific region particularly India and China rising fast. Asia pacific region is expected to be fastest growing region in hepatitis C diagnosis & treatment market. The African region is expected to be a laggard and will show at most a moderate rate of growth.

Globally the market for hepatitis C diagnosis & treatment is increasing rapidly. The major factor that derives the growth of hepatitis C diagnosis & treatment is the Shared needles to inject drugs. Furthermore increasing awareness in the health care and government taking steps is increasing the growth of hepatitis C diagnosis & treatment market.

More Inquire at https://www.marketresearchfuture.com/enquiry/1569 .

The report for Global Hepatitis C Diagnosis & Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis C Diagnosis & Treatment Market : Global Key Players - F. Hoffmann-La Roche Ltd, BMS, Merck & Co., Inc, Vertex Pharmaceuticals Incorporated here

News-ID: 902950 • Views:

More Releases from Market Research Future

Legg-Calve-Perthes Disease Market See Incredible Growth 2024-2031 | Non-Surgical Methods, Anti-Inflammatory Medications, Ibuprofen, Casting and Bracing
Legg-Calve-Perthes Disease Market See Incredible Growth 2024-2031 | Non-Surgical …
Legg-Calve-Perthes Disease Market Overview - The market for legg-calve-Perthes disease treatment is estimated to reach USD 400 million by 2030, growing at a CAGR of 4.60%. Legg-Calve-Perthes disease (LCPD) is a condition affecting the hip joint, primarily seen in children between the ages of 4 and 8. It occurs when blood flow to the femoral head (the "ball" of the hip joint) is temporarily disrupted, leading to bone death and potential deformity.
Passive Optical LAN Market Size, Share, Growth and Forecast to 2032
Passive Optical LAN Market Size, Share, Growth and Forecast to 2032
Passive Optical LAN Market Overview In today's digital age, where connectivity is paramount, the demand for robust and efficient network infrastructure continues to escalate. Traditional copper-based LAN (Local Area Network) systems are gradually being outpaced by newer, more advanced technologies. Among these innovations, Passive Optical LAN (POL) stands out as a game-changer. This article explores the burgeoning Passive Optical LAN market, its advantages, key drivers, and future prospects. Redefining Network Architecture with
Navigating Schizophrenia Care Market Expected to Expand to $8.06 Billion by 2030 | Johnson & Johnson, AstraZeneca, Eli Lilly, Alkermes
Navigating Schizophrenia Care Market Expected to Expand to $8.06 Billion by 2030 …
Schizophrenia Market Overview - The Schizophrenia Market Size was assessed at USD 5.5 billion in 2022 and is expected to expand from USD 5.76 billion in 2023 to USD 8.06 billion by 2030, with a compound annual growth rate (CAGR) of 4.9% during the forecast period (2023- 2030). The schizophrenia market is a significant segment within the pharmaceutical and mental healthcare industries, focused on addressing the complex needs of individuals living with
Revolutionizing Healing: Skin Graft Market Set to Grow at 7.01% CAGR, Reaching $7.36 Billion by 2032
Revolutionizing Healing: Skin Graft Market Set to Grow at 7.01% CAGR, Reaching $ …
Skin Graft Market Overview - In 2022, the skin graft market was estimated at USD 4.00 billion. The skin graft market is expected to increase from USD 4.28 billion in 2023 to USD 7.36 billion by 2032, with a compound annual growth rate (CAGR) of 7.01% over the forecast period (2023-2032). The skin graft market plays a crucial role in the field of dermatology and wound care, providing solutions for patients with

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each